The Institute for Global Food Security, Queen's University Belfast, 19 Chlorine Gardens, Belfast, Northern Ireland, BT9 5DL, UK.
Heidelberg Institute of Global Health (HIGH), Faculty of Medicine and University Hospital, Heidelberg, Germany.
Eur J Nutr. 2024 Aug;63(5):1471-1486. doi: 10.1007/s00394-024-03380-4. Epub 2024 Apr 21.
It has been proposed that a higher habitual protein intake may increase cancer risk, possibly via upregulated insulin-like growth factor signalling. Since a systematic evaluation of human studies on protein intake and cancer risk based on a standardised assessment of systematic reviews (SRs) is lacking, we carried out an umbrella review of SRs on protein intake in relation to risks of different types of cancer.
Following a pre-specified protocol (PROSPERO: CRD42018082395), we retrieved SRs on protein intake and cancer risk published before January 22th 2024, and assessed the methodological quality and outcome-specific certainty of the evidence using a modified version of AMSTAR 2 and NutriGrade, respectively. The overall certainty of evidence was rated according to predefined criteria.
Ten SRs were identified, of which eight included meta-analyses. Higher total protein intake was not associated with risks of breast, prostate, colorectal, ovarian, or pancreatic cancer incidence. The methodological quality of the included SRs ranged from critically low (kidney cancer), low (pancreatic, ovarian and prostate cancer) and moderate (breast and prostate cancer) to high (colorectal cancer). The outcome-specific certainty of the evidence underlying the reported findings on protein intake and cancer risk ranged from very low (pancreatic, ovarian and prostate cancer) to low (colorectal, ovarian, prostate, and breast cancer). Animal and plant protein intakes were not associated with cancer risks either at a low (breast and prostate cancer) or very low (pancreatic and prostate cancer) outcome-specific certainty of the evidence. Overall, the evidence for the lack of an association between protein intake and (i) colorectal cancer risk and (ii) breast cancer risk was rated as possible. By contrast, the evidence underlying the other reported results was rated as insufficient.
The present findings suggest that higher total protein intake may not be associated with the risk of colorectal and breast cancer, while conclusions on protein intake in relation to risks of other types of cancer are restricted due to insufficient evidence.
有人提出,较高的习惯性蛋白质摄入可能会增加癌症风险,这可能是通过上调胰岛素样生长因子信号来实现的。由于缺乏基于系统评价(SR)标准化评估的关于蛋白质摄入与癌症风险的人类研究的系统评价综述,我们对与不同类型癌症风险相关的蛋白质摄入的 SR 进行了伞式综述。
根据预先规定的方案(PROSPERO:CRD42018082395),我们检索了截至 2024 年 1 月 22 日之前发表的关于蛋白质摄入与癌症风险的 SR,并使用改良版 AMSTAR 2 和 NutriGrade 分别评估了证据的方法学质量和特定结局的确定性。根据预设标准对证据的总体确定性进行了评级。
确定了 10 项 SR,其中 8 项包含荟萃分析。较高的总蛋白质摄入量与乳腺癌、前列腺癌、结直肠癌、卵巢癌或胰腺癌的发病率无关。纳入 SR 的方法学质量从批判性低(肾癌)、低(胰腺癌、卵巢癌和前列腺癌)和中等(乳腺癌和前列腺癌)到高(结直肠癌)不等。报告的蛋白质摄入与癌症风险相关的发现的证据的特定结局确定性从非常低(胰腺癌、卵巢癌和前列腺癌)到低(结直肠癌、卵巢癌、前列腺癌和乳腺癌)不等。动物和植物蛋白质的摄入量与癌症风险也没有关联,无论是在特定结局确定性非常低(乳腺癌和前列腺癌)还是低(胰腺癌和前列腺癌)的情况下。总体而言,缺乏蛋白质摄入与(i)结直肠癌风险和(ii)乳腺癌风险之间关联的证据被评为可能。相比之下,其他报告结果的基础证据被评为不足。
本研究结果表明,较高的总蛋白质摄入可能与结直肠癌和乳腺癌的风险无关,而关于蛋白质摄入与其他类型癌症风险的关系的结论由于证据不足而受到限制。